<DOC>
	<DOCNO>NCT01884259</DOCNO>
	<brief_summary>This multicentre , randomise Phase II Pilot Study evaluate efficacy docetaxel , cisplatin 5-fluorouracil Cetuximab , follow Cetuximab radiotherapy .</brief_summary>
	<brief_title>Induction Chemotherapy With TP+5-FU TP+Cetuximab Followed Radioimmuptherapy Locally Advanced Not Resectable SCCHNN</brief_title>
	<detailed_description>It evaluate whether 5-FU replace immunotherapy cetuximab within taxane/cisplatin-containing induction-chemotherapy scheme advance carcinoma head neck . As 5-FU cause severe mucosal toxicity add known toxicity cisplatin , combination-therapy reduced toxicity efficacy would acceptable alternative patient .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Laryngeal Diseases</mesh_term>
	<mesh_term>Laryngeal Neoplasms</mesh_term>
	<mesh_term>Oropharyngeal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Histologically confirm local advance squamous cell carcinoma Larynx , Hypopharynx , Oropharynx Cavum oris stage III IV One measureable lesion ( CT oder MR ) Age 18 75 ( include ) Performance Score ECOG 0 1 Exclusion Criteria select : Distant metastasis ECOG Score &gt; 1 Prior radiation ( Head neck area ) Creatinin Clearance 60 ml/Âµl Acute infection Neuropathy grade 3 4 Myocardial Infarction within last 12 month Acute coronary syndrome othe clinically significant cardiovascular disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>local advance squamous cell carcinoma</keyword>
	<keyword>Larynx</keyword>
	<keyword>Hypopharynx</keyword>
	<keyword>Oropharynx</keyword>
	<keyword>Cavum oris</keyword>
	<keyword>docetaxel</keyword>
	<keyword>cisplatin</keyword>
	<keyword>5-fluorouracil</keyword>
	<keyword>Cetuximab</keyword>
</DOC>